Health: mRNA Covid vaccines may help fight cancer • FRANCE 24 English

Key Concepts

• mRNA COVID vaccines
• Immunotherapy
• Cancer treatment
• Immune system activation
• Tumor response
• Overall survival

mRNA Vaccines as a "Siren" for the Immune System in Cancer Patients

Researchers have discovered a significant additional benefit of mRNA COVID vaccines for certain cancer patients, beyond their initial role in saving lives during the pandemic. The core finding is that these vaccines act as a "siren," effectively activating the immune system throughout the body.

Study Details and Findings

A study conducted at MD Anderson Cancer Center in Texas involved 1,000 patients diagnosed with advanced lung cancer or melanoma. These patients were within 100 days of receiving approved immunotherapy drugs.

• Lung Cancer Patients: Lung cancer patients who received either the Pfizer or Moderna mRNA COVID vaccine demonstrated a significantly longer survival rate. They survived for approximately 37 months, which is nearly double the survival time of those who did not receive the vaccine.
• Mechanism of Action: Researchers hypothesize that the vaccine helps to "supercharge" the patients' immune systems, enhancing their ability to combat cancerous tumors. The mRNA vaccine appears to reprogram the immune system in a manner that makes immunotherapy more effective in fighting cancer.
• Improved Response to Immunotherapy: For patients who initially did not respond well to immunotherapy, the study observed a five-fold improvement in their overall survival when they also received the mRNA COVID vaccine.

Implications and Future Directions

These findings are generating optimism for the potential use of vaccines in treating a variety of cancers. However, this research emerges at a challenging juncture for mRNA vaccine development.

• Context of Funding Cuts: In August, US Health Secretary Robert F. Kennedy Jr. announced the cancellation of $500 million in mRNA development funding. This decision was based on the claim that mRNA vaccines failed to protect against respiratory infections like COVID and the flu, a perspective that contradicts scientific findings.
• Preliminary Nature of Findings: The researchers emphasize that the findings related to cancer treatment are preliminary.
• Next Steps: Plans are already underway for a Phase Three clinical trial, with the aim of enrolling patients by the end of the current year.

Synthesis/Conclusion

The research suggests that mRNA COVID vaccines possess a potent ability to stimulate the immune system, which can translate into improved outcomes for cancer patients undergoing immunotherapy. While these findings are promising and point towards a future where vaccines could be a therapeutic tool for cancer, they are still in the early stages of validation. The ongoing development and potential funding challenges for mRNA technology add a layer of complexity to the future of this research.